When antivirals backfire: An evaluation of favipiravir's clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

• Váldodahkkit: Khalid Al Sulaiman (Dahkki), Ohoud Aljuhani (Dahkki), Ghazwa B. Korayem (Dahkki), Ali F. Altebainawi (Dahkki), Mashael AlFaifi (Dahkki), Majed Nahari (Dahkki), Alaa Almagthali (Dahkki), Abrar K. Thabit (Dahkki), Raghad Alhajaji (Dahkki), Reham Alharbi (Dahkki), Khawla Kahtani (Dahkki), Abeer A. Alenazi (Dahkki), Aisha Alharbi (Dahkki), Munirah M. Alghwainm (Dahkki), Sara M. Alotaibi (Dahkki), Yazeed S. Alghamdi (Dahkki), Samar Alotaibi (Dahkki), Shaden H. Alonazi (Dahkki), Jumanah M. Almutairi (Dahkki), Ramesh Vishwakarma (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Elsevier, 2023-09-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Background: Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease. Yet, the findings on the use of favipiravir in critically ill patients with COVID-19 are inconsistent. Therefore, this study aimed to assess...